Jul 27, 2026 ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
Jul 14, 2026 ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
May 12, 2026 ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
Apr 27, 2026 Targeting underlying causes of neurodegenerative diseases | 2026 Bloom Burton & Co. Healthcare Investor Conference
Mar 25, 2026 ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
Mar 18, 2026 ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
Feb 4, 2026 ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026